Atherosclerosis and cardiovascular risk reduction with PPAR agonists

Current Atherosclerosis Reports

Volumn 9, Issue 4, 2007, Pages 274-280

  Kuusisto, Johanna ^b   Andrulionyte, Laura ^b   Laakso, Markku ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BEZAFIBRATE; CELL NUCLEUS RECEPTOR; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MURAGLITAZAR; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR; TRANSCRIPTION FACTOR; TROGLITAZONE;

ADIPOGENESIS; ATHEROSCLEROSIS; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ENERGY METABOLISM; GLUCOSE HOMEOSTASIS; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPID METABOLISM; LIVER TOXICITY; MACROPHAGE; MONOCYTE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; RISK REDUCTION; SIDE EFFECT; SMOOTH MUSCLE FIBER; STROKE; T LYMPHOCYTE; TRANSIENT ISCHEMIC ATTACK; VASCULAR SMOOTH MUSCLE; WEIGHT GAIN;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CLOFIBRIC ACID; HUMANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RISK REDUCTION BEHAVIOR; THIAZOLIDINEDIONES;

EID: 36049032363     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-007-0033-4     Document Type: Review

References (50)

1. Francis GA, Annicotte JS, Auwerx J: PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 2003, 3:186-191.
2. Wahli W, Braissant O, Desvergne B: Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, tipid metabolism and more. Chem Biol 1995, 2:261-266.
3. Kota BP, Huang TH, Roufogalis BD: An overview on biological mechanisms of PPARs. Pharmacol Res 2005, 51:85-94.
4. Argmann CA, Cock TA, Auwerx J: Peroxisome proliferator-activated receptor y. the more the merrier? EurJ Clin Invest 2005, 35:82-92.
5. Lee CH, Olson P, Hevener A, et al.: PPARδ regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 2006, 103:3444-3449.
6. Berger JP, Akiyama TE, Meinke PT: PPARs: therapeutic targets for metabolic diseases. Trends Pharmacol Sci 2005, 26:244-251.
7. Staels B, Vu-Dac N, Kosykh VA, et al.: Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995, 95:705-712.
8. Chinetti G, Lestavel S, Bocher V, et al.: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53-58.
9. Marx N, Sukhova GK, Collins T, et al.: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99:3125-3131.
10. Touyz RM, Schiffrin EL: Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vasc Pharmacol 2006, 45:19-28.
11. Delerive P, De Bosscher K, Besnard S, et al.: Peroxisome proliferator-activated receptor a negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J Biol Chem 1999, 274:32048-32054.
12. Gbaguidi FG, Chinetri G, Milosavljevic D, et al.: Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein tipase secretion and glycated LDL uptake by human macrophages. FEBS Lett 2002, 512:85-90.
13. Marx N, Mackman N, Schonbeck U, et al.: PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001, 103:213-219.
14. Marx N, Kehrle B, Kohlhammer K, et al.: PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002, 90:703-710.
15. Delerive P, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001, 169:453-459.
16. Evans M, Anderson RA, Graham J, et al.: Ciprofibrate therapy improves endothetial function and reduces potsprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2002, 101:1773-1779.
17. Playford DA, Watts CF, Best JD, Burke V: Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 2002, 90:1254-1257.
18. Flavell DM, Pineda Torra I, Jamshidi I, et al.: Variation in the PPAR gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia 2000, 43:673-80.
19. Flavell DM, Jamshidi Y, Hawe E, et al.: Peroxisome proliferator-activated receptor a gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002, 105:1440-1445.
20. Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M; STOP-NIDDM Study group: SNPs of the PPARa gene influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2007, 56:1181-1186.
21. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia-safety treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
22. Koskinen P, Mänttäri M, Manninen V, et al.: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820-825.
23. Rubins HB, Robins SJ, Collins D, et al.: Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
24. Tenenbaum A, Motto M, Fisman EZ, et al.: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154-1160.
25. Diabetes Atherocslerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary heart disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study: a randomized study. Lancet 2001, 357:905-910.
26. Keech A, Sirnes RJ, Barter P, et al.; for the FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study); randomized controlled trial. Lancet 2005, 366:1849-1861.
27. Vosper H, Khoudoli GA, Graham TL, Palmer CA: Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol Ther 2002, 95:47-62.
28. Bruemmer D, Blaschke F, Law RE: New targets for PPARgamma in the vessel wall: implications for restenosis. Int J Obes 2005, 29(SuppI 1):S26-S30.
29. Goetze S, Eilers F, Bungenstock A, et al.: PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biopbys Res Commun 2002, 293:1431-1437.
30. Ricote M, Li AC, Willson TM, et al.: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
31. Jiang C, Ting AT, Seed B: PPAR-g agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
32. Chinetti G, Gbaguidi FG, Griglio S, et al.: CLA-1/SR-B1 is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101:2411-2417.
33. Clark RB, Bishop Bailey D, Estrada Hernandez T, et al.: The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J Immunol 2000, 164:1364-1371.
34. Marx N, Duez H, Fruchart JC, Staels B: Peroxisome-activated receptors and atherogenesis. Regulators of gene expression in vascular cells. Circ Res 2004, 94:1168-1178.
35. Haffner SM, Greenberg AS, Weston WM, et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679-684.
36. Koshiyama H, Shimono D, Kuwamura N, et al.: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001, 86:3452-3456.
37. Deeb SS, Fajas S, Nemoto M, et al.: A Pro12AIa substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287.
38. Lindi VI, Uusitupa M, Lindström J, et al.: Association of the Pro12AIa polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002, 51:2581-2586.
39. Temelkova-Kurtschiev T, Hanefeld M, Chinetti G, et al.: Ala12AIa genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab 2004, 89:4234-4237.
40. Ridker PM, Cook NR, Cheng S, et al.: Alanine to proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 2003, 23:859-863.
41. Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796-2803.
42. Knowler WC, Hamman RF, Edelstein SL, et al.: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005, 54:1150-1156.
43. Gerstein HC, Yusuf S, Bosch J, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
44. Kahn SE, Haffner SM, Heise MA, et al.; for the ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N EnglJ Med 2006, 355:2477-2480.
45. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005, 366:1279-1289.
46. Oliver WR Jr, Shenk JL, Snaith MR: A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001, 98:5306-5311.
47. Hansen JB, Zhang H, Rasmussen TH: Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J Biol Chem 2001, 276:3175-3182.
48. Graham TL, Mookherjee C, Suckling KE, et al.: The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 2005, 182:381-384.
49. Andrulionyte L, Chiasson JL, Laakso M: SNPs of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12AIa substitution of PPARG2 predict the conversion from IGT to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2006, 55:2148-2152.
50. Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005, 294:2581-2586.